A Novel Defined PANoptosis-Related miRNA Signature for Predicting the Prognosis and Immune Characteristics in Clear Cell Renal Cell Carcinoma: A miRNA Signature for the Prognosis of ccRCC
Abstract
:1. Introduction
2. Results
2.1. Identification of Differentially Expressed miRNAs between Normal and Tumor Tissues
2.2. Development of the PANoptosis-Related Prognostic Signature Model
2.3. Assessment of the PANoptosis-Related Prognostic Signature Model
2.4. Clinical Characteristics of the Risk Score Model
2.5. The Relationship between Metabolic Process and Risk Groups
2.6. Characteristic Performance of the Tumor Microenvironment Cell Infiltration
2.7. Estimation of Immunotherapy and Chemotherapy Responses
2.8. Functional Enrichment Analysis of Distinctive miRNAs
3. Discussion
4. Materials and Methods
4.1. ccRCC Data Acquisition and Preprocessing
4.2. Identification of Differentially Expressed miRNAs
4.3. Establishment of Prognostic Risk Signature and Prediction Analysis
4.4. Clinical Characteristics of the Risk Score Model
4.5. Nomogram Construction and Evaluation
4.6. Pathway Enrichment Analysis
4.7. Estimation of Immune Cell Infiltration and Microenvironment Characterization
4.8. Cell Annotation and Single-Cell Trajectory Analysis
4.9. Prediction of Target Gene and Functional Analysis for miRNAs
4.10. Drug Sensitivity Analysis
4.11. Clinical Samples
4.12. Cell Culture
4.13. Cell Transfection
4.14. RNA Extraction and Real-Time Quantitative PCR
4.15. Cell Counting Kit-8 Assay
4.16. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021, 71, 7–33. [Google Scholar] [CrossRef]
- Rini, B.I.; Campbell, S.C.; Escudier, B. Renal cell carcinoma. Lancet 2009, 373, 1119–1132. [Google Scholar] [CrossRef] [PubMed]
- Xu, W.; Atkins, M.B.; McDermott, D.F. Checkpoint inhibitor immunotherapy in kidney cancer. Nat. Rev. Urol. 2020, 17, 137–150. [Google Scholar] [CrossRef] [PubMed]
- Hsieh, J.J.; Purdue, M.P.; Signoretti, S.; Swanton, C.; Albiges, L.; Schmidinger, M.; Heng, D.Y.; Larkin, J.; Ficarra, V. Renal cell carcinoma. Nat. Rev. Dis. Prim. 2017, 3, 17009. [Google Scholar] [CrossRef] [PubMed]
- Motzer, R.J.; Hutson, T.E.; Tomczak, P.; Michaelson, M.D.; Bukowski, R.M.; Rixe, O.; Oudard, S.; Negrier, S.; Szczylik, C.; Kim, S.T.; et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007, 356, 115–124. [Google Scholar] [CrossRef]
- Hahn, A.W.; Klaassen, Z.; Agarwal, N.; Haaland, B.; Esther, J.; Ye, X.Y.; Wang, X.; Pal, S.K.; Wallis, C.J.D. First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. Eur. Urol. Oncol. 2019, 2, 708–715. [Google Scholar] [CrossRef]
- Galluzzi, L.; Vitale, I.; Aaronson, S.A.; Abrams, J.M.; Adam, D.; Agostinis, P.; Alnemri, E.S.; Altucci, L.; Amelio, I.; Andrews, D.W.; et al. Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018, 25, 486–541. [Google Scholar] [CrossRef]
- Christgen, S.; Tweedell, R.E.; Kanneganti, T.D. Programming inflammatory cell death for therapy. Pharmacol. Ther. 2022, 232, 108010. [Google Scholar] [CrossRef] [PubMed]
- Kuriakose, T.; Man, S.M.; Malireddi, R.K.; Karki, R.; Kesavardhana, S.; Place, D.E.; Neale, G.; Vogel, P.; Kanneganti, T.D. ZBP1/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways. Sci. Immunol. 2016, 1, aag2045. [Google Scholar] [CrossRef]
- Zheng, M.; Kanneganti, T.D. The regulation of the ZBP1-NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PANoptosis). Immunol. Rev. 2020, 297, 26–38. [Google Scholar] [CrossRef]
- Wang, Y.; Kanneganti, T.D. From pyroptosis, apoptosis and necroptosis to PANoptosis: A mechanistic compendium of programmed cell death pathways. Comput. Struct. Biotechnol. J. 2021, 19, 4641–4657. [Google Scholar] [CrossRef]
- Banoth, B.; Tuladhar, S.; Karki, R.; Sharma, B.R.; Briard, B.; Kesavardhana, S.; Burton, A.; Kanneganti, T.D. ZBP1 promotes fungi-induced inflammasome activation and pyroptosis, apoptosis, and necroptosis (PANoptosis). J. Biol. Chem. 2020, 295, 18276–18283. [Google Scholar] [CrossRef] [PubMed]
- Ali Syeda, Z.; Langden, S.S.S.; Munkhzul, C.; Lee, M.; Song, S.J. Regulatory Mechanism of MicroRNA Expression in Cancer. Int. J. Mol. Sci. 2020, 21, 1723. [Google Scholar] [CrossRef] [PubMed]
- Rupaimoole, R.; Slack, F.J. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat. Rev. Drug. Discov. 2017, 16, 203–222. [Google Scholar] [CrossRef] [PubMed]
- Cochetti, G.; Cari, L.; Maula, V.; Cagnani, R.; Paladini, A.; Del Zingaro, M.; Nocentini, G.; Mearini, E. Validation in an Independent Cohort of MiR-122, MiR-1271, and MiR-15b as Urinary Biomarkers for the Potential Early Diagnosis of Clear Cell Renal Cell Carcinoma. Cancers 2022, 14, 1112. [Google Scholar] [CrossRef]
- Gan, X.G.; Wang, Z.H.; Xu, H.T. Mechanism of miRNA-141-3p in Calcium Oxalate-Induced Renal Tubular Epithelial Cell Injury via NLRP3-Mediated Pyroptosis. Kidney Blood Press. Res. 2022, 47, 300–308. [Google Scholar] [CrossRef]
- Wang, N.; Li, P.; Liu, W.; Wang, N.; Lu, Z.; Feng, J.; Zeng, X.; Yang, J.; Wang, Y.; Zhao, W. miR-141-3p suppresses proliferation and promotes apoptosis by targeting GLI2 in osteosarcoma cells. Oncol. Rep. 2018, 39, 747–754. [Google Scholar] [CrossRef]
- Tong, S.J.; Zhang, X.Y.; Guo, H.F.; Yang, J.; Qi, Y.P.; Lu, S. Study on effects of miR-141-3p in proliferation, migration, invasion and apoptosis of colon cancer cells by inhibiting Bcl2. Clin. Transl. Oncol. 2021, 23, 2526–2535. [Google Scholar] [CrossRef]
- Li, J.Z.; Li, J.; Wang, H.Q.; Li, X.; Wen, B.; Wang, Y.J. MiR-141-3p promotes prostate cancer cell proliferation through inhibiting kruppel-like factor-9 expression. Biochem. Biophys. Res. Commun. 2017, 482, 1381–1386. [Google Scholar] [CrossRef]
- Li, X.; Wang, Y.; Wang, Y.; He, X. MiR-141-3p ameliorates RIPK1-mediated necroptosis of intestinal epithelial cells in necrotizing enterocolitis. Aging (Albany NY) 2020, 12, 18073–18083. [Google Scholar] [CrossRef]
- Tan, C.; Liu, W.; Zheng, Z.H.; Wan, X.G. LncRNA HOTTIP inhibits cell pyroptosis by targeting miR-148a-3p/AKT2 axis in ovarian cancer. Cell. Biol. Int. 2021, 45, 1487–1497. [Google Scholar] [CrossRef] [PubMed]
- Zhou, H.; Jia, X.; Yang, F.; Shi, P. miR-148a-3p suppresses the progression of acute myeloid leukemia via targeting cyclin-dependent kinase 6 (CDK6). Bioengineered 2021, 12, 4508–4519. [Google Scholar] [CrossRef] [PubMed]
- Xu, C.; Zhou, G.; Sun, Z.; Zhang, Z.; Zhao, H.; Jiang, X. miR-148a-3p inhibits the proliferation and migration of bladder cancer via regulating the expression of ROCK-1. PeerJ 2022, 10, e12724. [Google Scholar] [CrossRef]
- Xu, J.; Sun, M.; Li, X.; Huang, L.; Gao, Z.; Gao, J.; Xie, A. MicroRNA expression profiling after recurrent febrile seizures in rat and emerging role of miR-148a-3p/SYNJ1 axis. Sci. Rep. 2021, 11, 1262. [Google Scholar] [CrossRef] [PubMed]
- Wang, W.; Shi, Q.; Wang, S.; Zhang, H.; Xu, S. Ammonia regulates chicken tracheal cell necroptosis via the LncRNA-107053293/MiR-148a-3p/FAF1 axis. J. Hazard. Mater. 2020, 386, 121626. [Google Scholar] [CrossRef] [PubMed]
- Rana, S.; Espinosa-Diez, C.; Ruhl, R.; Chatterjee, N.; Hudson, C.; Fraile-Bethencourt, E.; Agarwal, A.; Khou, S.; Thomas, C.R., Jr.; Anand, S. Differential regulation of microRNA-15a by radiation affects angiogenesis and tumor growth via modulation of acid sphingomyelinase. Sci. Rep. 2020, 10, 5581. [Google Scholar] [CrossRef]
- Chen, X.; Cao, R.; Liu, H.; Zhang, T.; Yuan, X.; Xu, S. MicroRNA15a5ptargeting oncogene YAP1 inhibits cell viability and induces cell apoptosis in cervical cancer cells. Int. J. Mol. Med. 2020, 46, 1301–1310. [Google Scholar]
- Li, X.; Chen, M.; Shi, Q.; Zhang, H.; Xu, S. Hydrogen sulfide exposure induces apoptosis and necroptosis through lncRNA3037/miR-15a/BCL2-A20 signaling in broiler trachea. Sci. Total Environ. 2020, 699, 134296. [Google Scholar] [CrossRef]
- Wang, B.; Cui, Y.; Zhang, Q.; Wang, S.; Xu, S. Selenomethionine alleviates LPS-induced JNK/NLRP3 inflammasome-dependent necroptosis by modulating miR-15a and oxidative stress in chicken lungs. Metallomics 2021, 13, mfab048. [Google Scholar] [CrossRef]
- Fu, Y.; Shen, J.; Liu, F.; Zhang, H.; Zheng, Y.; Jiang, X. Andrographolide Suppresses Pyroptosis in Mycobacterium tuberculosis-Infected Macrophages via the microRNA-155/Nrf2 Axis. Oxid. Med. Cell. Longev. 2022, 2022, 1885066. [Google Scholar] [CrossRef]
- Yu, Q.; Xu, X.P.; Yin, X.M.; Peng, X.Q. miR-155-5p increases the sensitivity of liver cancer cells to adriamycin by regulating ATG5-mediated autophagy. Neoplasma 2021, 68, 87–95. [Google Scholar] [CrossRef] [PubMed]
- Li, S.; Zhang, T.; Zhou, X.; Du, Z.; Chen, F.; Luo, J.; Liu, Q. The tumor suppressor role of miR-155-5p in gastric cancer. Oncol. Lett. 2018, 16, 2709–2714. [Google Scholar] [CrossRef]
- Bhattacharya, S.; Chalk, A.M.; Ng, A.J.; Martin, T.J.; Zannettino, A.C.; Purton, L.E.; Lu, J.; Baker, E.K.; Walkley, C.R. Increased miR-155-5p and reduced miR-148a-3p contribute to the suppression of osteosarcoma cell death. Oncogene 2016, 35, 5282–5294. [Google Scholar] [CrossRef]
- Zhang, J.; Chen, Y.; Gao, W. Puerarin protects against human retinal endothelial cells injury induced by high glucose via regulating miR-16-5p/CASP1 axis. Gen. Physiol. Biophys. 2021, 40, 235–243. [Google Scholar] [CrossRef] [PubMed]
- Wang, Z.; Hu, S.; Li, X.; Liu, Z.; Han, D.; Wang, Y.; Wei, L.; Zhang, G.; Wang, X. MiR-16-5p suppresses breast cancer proliferation by targeting ANLN. BMC Cancer 2021, 21, 1188. [Google Scholar] [CrossRef]
- Wang, F.; Wang, W.; Lu, L.; Xie, Y.; Yan, J.; Chen, Y.; Di, C.; Gan, L.; Si, J.; Zhang, H.; et al. MicroRNA165p regulates cell survival, cell cycle and apoptosis by targeting AKT3 in prostate cancer cells. Oncol. Rep. 2020, 44, 1282–1292. [Google Scholar] [CrossRef] [PubMed]
- Wang, L.; Shi, X.; Zheng, S.; Xu, S. Selenium deficiency exacerbates LPS-induced necroptosis by regulating miR-16-5p targeting PI3K in chicken tracheal tissue. Metallomics 2020, 12, 562–571. [Google Scholar] [CrossRef]
- Zhao, M.W.; Yang, P.; Zhao, L.L. Chlorpyrifos activates cell pyroptosis and increases susceptibility on oxidative stress-induced toxicity by miR-181/SIRT1/PGC-1α/Nrf2 signaling pathway in human neuroblastoma SH-SY5Y cells: Implication for association between chlorpyrifos and Parkinson’s disease. Environ. Toxicol. 2019, 34, 699–707. [Google Scholar]
- Xing, X.; Xu, T.; Liu, B.; Guo, Q. LncRNA SNHG5 can Regulate the Proliferation and Migration of Diffuse Large B Cell Lymphoma Progression via Targeting miR-181-5p/XIAP. J. Cancer 2022, 13, 784–792. [Google Scholar] [CrossRef]
- Zhang, W.; Sun, X.; Shi, X.; Qi, X.; Shang, S.; Lin, H. Subacute Cadmium Exposure Induces Necroptosis in Swine Lung via Influencing Th1/Th2 Balance. Biol. Trace Elem. Res. 2023, 201, 220–228. [Google Scholar] [CrossRef]
- Cui, Y.; Yin, K.; Gong, Y.; Qu, Y.; Liu, H.; Lin, H. Atrazine induces necroptosis by miR-181-5p targeting inflammation and glycometabolism in carp lymphocytes. Fish Shellfish Immunol. 2019, 94, 730–738. [Google Scholar] [CrossRef]
- Ke, R.; Wang, Y.; Hong, S.; Xiao, L. Endoplasmic reticulum stress related factor IRE1α regulates TXNIP/NLRP3-mediated pyroptosis in diabetic nephropathy. Exp. Cell Res. 2020, 396, 112293. [Google Scholar] [CrossRef] [PubMed]
- Guan, H.; You, Z.; Wang, C.; Fang, F.; Peng, R.; Mao, L.; Xu, B.; Chen, M. MicroRNA-200a suppresses prostate cancer progression through BRD4/AR signaling pathway. Cancer Med. 2019, 8, 1474–1485. [Google Scholar] [CrossRef] [PubMed]
- Guo, T.; Zhang, Y.; Qu, X.; Che, X.; Li, C.; Fan, Y.; Wan, X.; Ma, R.; Hou, K.; Zhou, H.; et al. miR-200a enhances TRAIL-induced apoptosis in gastric cancer cells by targeting A20. Cell Biol. Int. 2018, 42, 506–514. [Google Scholar] [CrossRef]
- Liang, X.L.; Wang, Y.L.; Wang, P.R. MiR-200a with CDC7 as a direct target declines cell viability and promotes cell apoptosis in Wilm’s tumor via Wnt/β-catenin signaling pathway. Mol. Cell. Biochem. 2021, 476, 2409–2420. [Google Scholar] [CrossRef]
- Huang, Y.; Bao, T.; Li, Z.; Ji, G.; Zhang, L. Function of miR-200a in proliferation and apoptosis of non-small cell lung cancer cells. Oncol. Lett. 2020, 20, 1256–1262. [Google Scholar] [CrossRef]
- Yang, T.; Cao, C.; Yang, J.; Liu, T.; Lei, X.G.; Zhang, Z.; Xu, S. miR-200a-5p regulates myocardial necroptosis induced by Se deficiency via targeting RNF11. Redox Biol. 2018, 15, 159–169. [Google Scholar] [CrossRef]
- Jiang, R.; Chen, X.; Ge, S.; Wang, Q.; Liu, Y.; Chen, H.; Xu, J.; Wu, J. MiR-21-5p Induces Pyroptosis in Colorectal Cancer via TGFBI. Front. Oncol. 2020, 10, 610545. [Google Scholar] [CrossRef]
- Xue, Z.; Xi, Q.; Liu, H.; Guo, X.; Zhang, J.; Zhang, Z.; Li, Y.; Yang, G.; Zhou, D.; Yang, H.; et al. miR-21 promotes NLRP3 inflammasome activation to mediate pyroptosis and endotoxic shock. Cell Death Dis. 2019, 10, 461. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Wang, Y.; Xue, J.; Liang, W.; Zhang, Z.; Yang, X.; Qiao, Z.; Jiang, Y.; Wang, J.; Cao, X.; et al. Co-treatment with miR-21-5p inhibitor and Aurora kinase inhibitor reversine suppresses breast cancer progression by targeting sprouty RTK signaling antagonist 2. Bioengineered 2022, 13, 455–468. [Google Scholar] [CrossRef]
- Li, X.; Chen, D.; Li, M.; Gao, X.; Shi, G.; Zhao, H. The CADM2/Akt pathway is involved in the inhibitory effect of miR-21-5p downregulation on proliferation and apoptosis in esophageal squamous cell carcinoma cells. Chem.-Biol. Interact. 2018, 288, 76–82. [Google Scholar] [CrossRef] [PubMed]
- Wang, N.; Liu, D. Identification and Validation a Necroptosis-related Prognostic Signature and Associated Regulatory Axis in Stomach Adenocarcinoma. OncoTargets Ther. 2021, 14, 5373–5383. [Google Scholar] [CrossRef] [PubMed]
- Jiang, Z.; Chen, J.; Chen, J.; Lei, Z.; Chen, H.; Wu, J.; Bai, X.; Wanyan, P.; Yu, Q. Anti-inflammatory effects of paeoniflorin caused by regulation of the hif1a/miR-210/caspase1/GSDMD signaling pathway in astrocytes: A novel strategy for hypoxia-induced brain injury in rats. Immunopharmacol. Immunotoxicol. 2021, 43, 410–418. [Google Scholar] [CrossRef]
- Du, Y.; Wei, N.; Ma, R.; Jiang, S.; Song, D. A miR-210-3p regulon that controls the Warburg effect by modulating HIF-1α and p53 activity in triple-negative breast cancer. Cell Death Dis. 2020, 11, 731. [Google Scholar] [CrossRef]
- Ren, J.; Li, X.; Dong, H.; Suo, L.; Zhang, J.; Zhang, L.; Zhang, J. miR-210-3p regulates the proliferation and apoptosis of non-small cell lung cancer cells by targeting SIN3A. Exp. Ther. Med. 2019, 18, 2565–2573. [Google Scholar] [CrossRef]
- Petanidis, S.; Domvri, K.; Porpodis, K.; Anestakis, D.; Freitag, L.; Hohenforst-Schmidt, W.; Tsavlis, D.; Zarogoulidis, K. Inhibition of kras-derived exosomes downregulates immunosuppressive BACH2/GATA-3 expression via RIP-3 dependent necroptosis and miR-146/miR-210 modulation. Biomed. Pharmacother. 2020, 122, 109461. [Google Scholar] [CrossRef]
- Tian, J.; Zhou, D.; Xiang, L.; Liu, X.; Zhang, H.; Wang, B.; Xie, B. MiR-223-3p inhibits inflammation and pyroptosis in monosodium urate-induced rats and fibroblast-like synoviocytes by targeting NLRP3. Clin. Exp. Immunol. 2021, 204, 396–410. [Google Scholar] [CrossRef]
- Xia, Y.; Zhou, K.; Sun, M.; Shu, R.; Qian, J.; Xie, Y. The miR-223-3p Regulates Pyroptosis Through NLRP3-Caspase 1-GSDMD Signal Axis in Periodontitis. Inflammation 2021, 44, 2531–2542. [Google Scholar] [CrossRef] [PubMed]
- Zhao, S.; Tan, Y.; Qin, J.; Xu, H.; Liu, L.; Wan, H.; Zhang, C.; Fan, W.; Qu, S. MicroRNA-223-3p promotes pyroptosis of cardiomyocyte and release of inflammasome factors via downregulating the expression level of SPI1 (PU.1). Toxicology 2022, 476, 153252. [Google Scholar] [CrossRef]
- Richie, J.P. Re: miR-223-3p Regulates Cell Growth and Apoptosis via FBXW7 Suggesting an Oncogenic Role in Human Testicular Germ Cell Tumors. J. Urol. 2018, 199, 1114. [Google Scholar] [CrossRef]
- Chai, B.; Guo, Y.; Cui, X.; Liu, J.; Suo, Y.; Dou, Z.; Li, N. MiR-223-3p promotes the proliferation, invasion and migration of colon cancer cells by negative regulating PRDM1. Am. J. Transl. Res. 2019, 11, 4516–4523. [Google Scholar] [PubMed]
- Feng, Q.; He, P.; Wang, Y. MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer. Gene 2018, 658, 152–158. [Google Scholar] [CrossRef]
- Qin, D.; Wang, X.; Li, Y.; Yang, L.; Wang, R.; Peng, J.; Essandoh, K.; Mu, X.; Peng, T.; Han, Q.; et al. MicroRNA-223-5p and -3p Cooperatively Suppress Necroptosis in Ischemic/Reperfused Hearts. J. Biol. Chem. 2016, 291, 20247–20259. [Google Scholar] [CrossRef]
- Huang, G.; Xue, J.; Sun, X.; Wang, J.; Yu, L.L. Necroptosis in 3-chloro-1, 2-propanediol (3-MCPD)-dipalmitate-induced acute kidney injury in vivo and its repression by miR-223-3p. Toxicology 2018, 406–407, 33–43. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Jiao, J.; Ren, P.; Wu, M. Upregulation of miRNA-223-3p ameliorates RIP3-mediated necroptosis and inflammatory responses via targeting RIP3 after spinal cord injury. J. Cell. Biochem. 2019, 120, 11582–11592. [Google Scholar] [CrossRef] [PubMed]
- Cui, Y.; Wang, X.; Lin, F.; Li, W.; Zhao, Y.; Zhu, F.; Yang, H.; Rao, M.; Li, Y.; Liang, H.; et al. MiR-29a-3p Improves Acute Lung Injury by Reducing Alveolar Epithelial Cell PANoptosis. Aging Dis. 2022, 13, 899–909. [Google Scholar] [CrossRef]
- Kaymak, I.; Williams, K.S.; Cantor, J.R.; Jones, R.G. Immunometabolic Interplay in the Tumor Microenvironment. Cancer Cell 2021, 39, 28–37. [Google Scholar] [CrossRef]
- Vitale, I.; Manic, G.; Coussens, L.M.; Kroemer, G.; Galluzzi, L. Macrophages and Metabolism in the Tumor Microenvironment. Cell Metab. 2019, 30, 36–50. [Google Scholar] [CrossRef]
- Liu, J.; Hong, M.; Li, Y.; Chen, D.; Wu, Y.; Hu, Y. Programmed Cell Death Tunes Tumor Immunity. Front. Immunol. 2022, 13, 847345. [Google Scholar] [CrossRef]
- Mao, X.; Xu, J.; Wang, W.; Liang, C.; Hua, J.; Liu, J.; Zhang, B.; Meng, Q.; Yu, X.; Shi, S. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives. Mol. Cancer 2021, 20, 131. [Google Scholar] [CrossRef]
- Wang, Y.; Navin, N.E. Advances and applications of single-cell sequencing technologies. Mol. Cell 2015, 58, 598–609. [Google Scholar] [CrossRef] [PubMed]
- Lovett, M. The applications of single-cell genomics. Hum. Mol. Genet. 2013, 22, R22–R26. [Google Scholar] [CrossRef] [PubMed]
- Wei, C.; Chen, M.; Deng, W.; Bie, L.; Ma, Y.; Zhang, C.; Liu, K.; Shen, W.; Wang, S.; Yang, C.; et al. Characterization of gastric cancer stem-like molecular features, immune and pharmacogenomic landscapes. Brief. Bioinform. 2022, 23, bbab386. [Google Scholar] [CrossRef] [PubMed]
- Merino, D.M.; McShane, L.M.; Fabrizio, D.; Funari, V.; Chen, S.J.; White, J.R.; Wenz, P.; Baden, J.; Barrett, J.C.; Chaudhary, R.; et al. Establishing guidelines to harmonize tumor mutational burden (TMB): In silico assessment of variation in TMB quantification across diagnostic platforms: Phase I of the Friends of Cancer Research TMB Harmonization Project. J. Immunother. Cancer 2020, 8, e000147. [Google Scholar] [CrossRef] [PubMed]
- Valero, C.; Lee, M.; Hoen, D.; Wang, J.; Nadeem, Z.; Patel, N.; Postow, M.A.; Shoushtari, A.N.; Plitas, G.; Balachandran, V.P.; et al. The association between tumor mutational burden and prognosis is dependent on treatment context. Nat. Genet. 2021, 53, 11–15. [Google Scholar] [CrossRef]
- Swanson, K.V.; Deng, M.; Ting, J.P. The NLRP3 inflammasome: Molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 2019, 19, 477–489. [Google Scholar] [CrossRef]
- Lamkanfi, M.; Malireddi, R.K.; Kanneganti, T.D. Fungal zymosan and mannan activate the cryopyrin inflammasome. J. Biol. Chem. 2009, 284, 20574–20581. [Google Scholar] [CrossRef]
- Cochetti, G.; Rossi de Vermandois, J.A.; Maula, V.; Giulietti, M.; Cecati, M.; Del Zingaro, M.; Cagnani, R.; Suvieri, C.; Paladini, A.; Mearini, E. Role of miRNAs in prostate cancer: Do we really know everything? Urol. Oncol. 2020, 38, 623–635. [Google Scholar] [CrossRef]
- Cochetti, G.; Rossi de Vermandois, J.A.; Maula, V.; Cari, L.; Cagnani, R.; Suvieri, C.; Balducci, P.M.; Paladini, A.; Del Zingaro, M.; Nocentini, G.; et al. Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: A single centre, prospective, blinded clinical trial. Urol. Oncol. 2022, 40, 105.e111–105.e118. [Google Scholar] [CrossRef]
- Place, D.E.; Lee, S.; Kanneganti, T.D. PANoptosis in microbial infection. Curr. Opin. Microbiol. 2021, 59, 42–49. [Google Scholar] [CrossRef]
- Karki, R.; Sharma, B.R.; Lee, E.; Banoth, B.; Malireddi, R.K.S.; Samir, P.; Tuladhar, S.; Mummareddy, H.; Burton, A.R.; Vogel, P.; et al. Interferon regulatory factor 1 regulates PANoptosis to prevent colorectal cancer. JCI Insight 2020, 5, e136720. [Google Scholar] [CrossRef]
- Li, J.; Huang, L.; He, Z.; Chen, M.; Ding, Y.; Yao, Y.; Duan, Y.; Zixuan, L.; Qi, C.; Zheng, L.; et al. Andrographolide Suppresses the Growth and Metastasis of Luminal-Like Breast Cancer by Inhibiting the NF-κB/miR-21-5p/PDCD4 Signaling Pathway. Front. Cell Dev. Biol. 2021, 9, 643525. [Google Scholar] [CrossRef]
- Su, Y.S.; Kuo, M.Z.; Kuo, Y.T.; Huang, S.W.; Lee, C.J.; Su, Z.Y.; Ni, Y.H.; Li, D.K.; Wu, T.Y. Diterpenoid anthraquinones as chemopreventive agents altered microRNA and transcriptome expressions in cancer cells. Biomed. Pharmacother. 2021, 136, 111260. [Google Scholar] [CrossRef]
- de Vasconcelos, N.M.; Van Opdenbosch, N.; Van Gorp, H.; Martin-Perez, R.; Zecchin, A.; Vandenabeele, P.; Lamkanfi, M. An Apoptotic Caspase Network Safeguards Cell Death Induction in Pyroptotic Macrophages. Cell Rep. 2020, 32, 107959. [Google Scholar] [CrossRef] [PubMed]
- Haneklaus, M.; Gerlic, M.; Kurowska-Stolarska, M.; Rainey, A.A.; Pich, D.; McInnes, I.B.; Hammerschmidt, W.; O’Neill, L.A.; Masters, S.L. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1beta production. J. Immunol. 2012, 189, 3795–3799. [Google Scholar] [CrossRef] [PubMed]
- Bauernfeind, F.; Rieger, A.; Schildberg, F.A.; Knolle, P.A.; Schmid-Burgk, J.L.; Hornung, V. NLRP3 inflammasome activity is negatively controlled by miR-223. J. Immunol. 2012, 189, 4175–4181. [Google Scholar] [CrossRef]
- Latz, E.; Xiao, T.S.; Stutz, A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 2013, 13, 397–411. [Google Scholar] [CrossRef]
- Senbabaoglu, Y.; Gejman, R.S.; Winer, A.G.; Liu, M.; Van Allen, E.M.; de Velasco, G.; Miao, D.; Ostrovnaya, I.; Drill, E.; Luna, A.; et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 2016, 17, 231. [Google Scholar] [CrossRef]
- Chen, D.S.; Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 2017, 541, 321–330. [Google Scholar] [CrossRef] [PubMed]
- Hegde, P.S.; Chen, D.S. Top 10 Challenges in Cancer Immunotherapy. Immunity 2020, 52, 17–35. [Google Scholar] [CrossRef]
- van der Burg, S.H.; Arens, R.; Ossendorp, F.; van Hall, T.; Melief, C.J. Vaccines for established cancer: Overcoming the challenges posed by immune evasion. Nat. Rev. Cancer 2016, 16, 219–233. [Google Scholar] [CrossRef]
- Hegde, P.S.; Karanikas, V.; Evers, S. The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. Clin. Cancer Res. 2016, 22, 1865–1874. [Google Scholar] [CrossRef]
- Thakur, M.D.; Franz, C.J.; Brennan, L.; Brouwer-Visser, J.; Tam, R.; Korski, K.; Koeppen, H.; Ziai, J.; Babitzki, G.; Ranchere-Vince, D.; et al. Immune contexture of paediatric cancers. Eur. J. Cancer 2022, 170, 179–193. [Google Scholar] [CrossRef] [PubMed]
- McDermott, D.F.; Huseni, M.A.; Atkins, M.B.; Motzer, R.J.; Rini, B.I.; Escudier, B.; Fong, L.; Joseph, R.W.; Pal, S.K.; Reeves, J.A.; et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 2018, 24, 749–757. [Google Scholar] [CrossRef] [PubMed]
- Xu, D.; Wang, Z.; Xia, Y.; Shao, F.; Xia, W.; Wei, Y.; Li, X.; Qian, X.; Lee, J.H.; Du, L.; et al. The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis. Nature 2020, 580, 530–535. [Google Scholar] [CrossRef] [PubMed]
Characteristics | Variable | Total (n = 511) | Train Cohort (n = 256) | Test Cohort (n = 255) | Chi-Square (p) |
---|---|---|---|---|---|
Age | ≤65 | 338 (66.14%) | 170 (66.41%) | 168 (65.88%) | 0.9004 |
>65 | 173 (33.86%) | 86 (33.59%) | 87 (34.12%) | ||
Gender | Male | 332 (64.97%) | 169 (66.02%) | 163 (63.92%) | 0.6198 |
Female | 179 (35.03%) | 87 (33.98%) | 92 (36.08%) | ||
Grade | G1 | 13 (2.54%) | 8 (3.13%) | 5 (1.96%) | 0.202 |
G2 | 215 (42.07%) | 110 (42.97%) | 105 (41.18%) | ||
G3 | 201 (39.33%) | 95 (37.11%) | 106 (41.57%) | ||
G4 | 74 (14.48%) | 36 (14.06%) | 38 (14.9%) | ||
Unknown | 8 (1.57%) | 7 (2.73%) | 1 (0.39%) | ||
Pathologic stage | Stage I | 251 (49.12%) | 125 (48.83%) | 126 (49.41%) | 0.9046 |
Stage II | 55 (10.76%) | 29 (11.33%) | 26 (10.2%) | ||
Stage III | 123 (24.07%) | 59 (23.05%) | 64 (25.1%) | ||
Stage IV | 82 (16.05%) | 43 (16.8%) | 39 (15.29%) | ||
Tumor (T) | T1 | 257 (50.29%) | 128 (50%) | 129 (50.59%) | 0.8356 |
T2 | 67 (13.11%) | 34 (13.28%) | 33 (12.94%) | ||
T3 | 176 (34.44%) | 87 (33.98%) | 89 (34.9%) | ||
T4 | 11 (2.15%) | 7 (2.73%) | 4 (1.57%) | ||
Node (N) | N0 | 227 (44.42%) | 107 (41.8%) | 120 (47.06%) | 0.1988 |
N1 | 16 (3.13%) | 11 (4.3%) | 5 (1.96%) | ||
Unknown | 268 (52.45%) | 138 (53.91%) | 130 (50.98%) | ||
Metastasis (M) | M0 | 405 (79.26%) | 202 (78.91%) | 203 (79.61%) | 0.4726 |
M1 | 77 (15.07%) | 42 (16.41%) | 35 (13.73%) | ||
Unknown | 29 (5.68%) | 12 (4.69%) | 17 (6.67%) | ||
Survival status | Alive | 340 (66.54%) | 170 (66.41%) | 170 (66.67%) | 0.6576 |
Dead | 171 (33.46%) | 86 (33.59%) | 85 (33.33%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wang, Y.; Zhou, J.; Zhang, N.; Zhu, Y.; Zhong, Y.; Wang, Z.; Jin, H.; Wang, X. A Novel Defined PANoptosis-Related miRNA Signature for Predicting the Prognosis and Immune Characteristics in Clear Cell Renal Cell Carcinoma: A miRNA Signature for the Prognosis of ccRCC. Int. J. Mol. Sci. 2023, 24, 9392. https://doi.org/10.3390/ijms24119392
Wang Y, Zhou J, Zhang N, Zhu Y, Zhong Y, Wang Z, Jin H, Wang X. A Novel Defined PANoptosis-Related miRNA Signature for Predicting the Prognosis and Immune Characteristics in Clear Cell Renal Cell Carcinoma: A miRNA Signature for the Prognosis of ccRCC. International Journal of Molecular Sciences. 2023; 24(11):9392. https://doi.org/10.3390/ijms24119392
Chicago/Turabian StyleWang, Yanmei, Jia Zhou, Nan Zhang, Yiran Zhu, Yiming Zhong, Zhuo Wang, Hongchuan Jin, and Xian Wang. 2023. "A Novel Defined PANoptosis-Related miRNA Signature for Predicting the Prognosis and Immune Characteristics in Clear Cell Renal Cell Carcinoma: A miRNA Signature for the Prognosis of ccRCC" International Journal of Molecular Sciences 24, no. 11: 9392. https://doi.org/10.3390/ijms24119392